パーキンソン病の世界市場レポート 2025年

パーキンソン病市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.2％で49億8,000万米ドルに成長します。予測期間中に予測される成長は、パーキンソン病の症状に対する認知度の向上、政府のイニシアチブの強化、ヘルスケア支出の増加、パーキンソン病の臨床試験数の増加、遺伝子治療の採用拡大によってもたらされます。この期間の主な動向には、技術の進歩、政府の継続的な取り組みと資金提供、診断における人工知能の統合、革新的なソリューション、個別化医療への移行などが含まれます。

神経変性疾患の有病率の増加は、パーキンソン病市場の成長を促進すると予想されます。神経変性疾患は、脳や神経系におけるニューロンの進行性の変性や機能喪失を特徴とする疾患群です。高齢化、遺伝的素因、環境の影響、診断の向上、慢性的な健康状態、ライフスタイルの変化など、いくつかの要因がこれらの疾患の有病率の上昇に寄与しています。パーキンソン病は、神経変性疾患の根本的なメカニズムの解明、潜在的な治療標的の同定、革新的な治療アプローチの開発など、神経変性疾患の理解を進める上で重要な役割を果たしています。例えば、2022年4月、欧州脳会議（European Brain Council）は、600を超える神経疾患と300近くの精神疾患が世界中で数百万人に影響を及ぼしており、6,500万人がてんかんに苦しんでいると報告しました。欧州だけでも1,050万人が認知症を患っており、2050年には1,870万人に増加すると予測されています。その結果、神経変性疾患の有病率の増加がパーキンソン病市場の拡大に拍車をかけています。

パーキンソン病市場の主要企業は、進行したパーキンソン病患者の運動機能を強化し、継続的な症状管理を提供するために、レボドパベースの治療などの革新的な治療ソリューションに注力しています。レボドパベースの治療では、脳内でドパミンに変換する薬であるレボドパを使用して症状を緩和し、運動機能を改善します。例えば、2024年10月、米国のバイオ医薬品会社であるアッヴィ社は、パーキンソン病の治療用に設計されたレボドパとカルビドパを含む併用療法であるVYALEVのFDA承認を取得しました。この製剤は、レボドパが脳に到達する前に分解されるのを防ぐことによりレボドパの有効性を高め、ドーパミン濃度を増加させる。振戦、固縮、徐脈などの運動症状を効果的に改善し、患者さんの日常生活の維持やQOLの向上に貢献します。本薬は、運動機能の変動を経験するパーキンソン病の患者にとって重要な治療ソリューションと考えられています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界パーキンソン病 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のパーキンソン病市場：成長率分析
• 世界のパーキンソン病市場の実績：規模と成長, 2019-2024
• 世界のパーキンソン病市場の予測：規模と成長, 2024-2029, 2034F
• 世界パーキンソン病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のパーキンソン病市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドーパミン作動薬
• カテコール-O-メチルトランスフェラーゼ阻害剤
• モノアミン酸化酵素B阻害剤
• 抗コリン薬
• カルビドパ-レボドパ
• その他の薬物クラス
• 世界のパーキンソン病市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 腸内注入
• 皮下
• その他の投与経路
• 世界のパーキンソン病市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小売薬局
• 病院薬局
• オンライン薬局
• 世界のパーキンソン病市場患者ケア設定別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 病院
• 世界のパーキンソン病市場ドーパミン作動薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 麦角誘導体
• 非麦角誘導体
• 世界のパーキンソン病市場カテコール-O-メチルトランスフェラーゼ（COMT）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エンタカポン
• トルカポン
• オピカポン
• 世界のパーキンソン病市場モノアミン酸化酵素B（MAO-B）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• セレギリン
• ラサギリン
• サフィナミド
• 世界のパーキンソン病市場抗コリン薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• トリヘキシフェニジル
• ベンツトロピン
• プロシクリジン
• 世界のパーキンソン病市場カルビドパ・レボドパのサブセグメンテーション（種類別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 即放性製剤
• 徐放性製剤
• 吸入および腸内ゲル製剤
• 世界のパーキンソン病市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アマンタジンおよび誘導体
• アデノシンA2A受容体拮抗薬
• グルタミン酸拮抗薬

第7章 地域別・国別分析

• 世界のパーキンソン病市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のパーキンソン病市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• パーキンソン病市場：競合情勢
• パーキンソン病市場：企業プロファイル
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • UCB S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eisai Co. Ltd.
• Kyowa Kirin Co. Ltd.
• Amneal Pharmaceuticals Inc.
• Neurocrine Biosciences Inc.
• Supernus Pharmaceuticals Inc.
• Sunovion Pharmaceuticals Inc.
• Intracellular Therapies Inc.
• Voyager Therapeutics Inc.
• Sage Therapeutics Inc.
• Adamas Pharmaceuticals Inc.
• Sun Pharma Advanced Research Company Ltd.
• Neuraly Inc.
• Mitsubishi Tanabe Pharma Corporation
• Athira Pharma Inc.
• VistaGen Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• パーキンソン病市場2029：新たな機会を提供する国
• パーキンソン病市場2029：新たな機会を提供するセグメント
• パーキンソン病市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Parkinson's disease is a degenerative neurological disorder that impacts movement due to the loss of dopamine-producing cells in the brain. It primarily results in tremors, muscle stiffness, slowed movements, and balance issues. Treatment typically includes medications such as levodopa to manage symptoms, often supplemented with physical therapy and, in some cases, surgical options such as deep brain stimulation.

The main classes of drugs used to treat Parkinson's disease consist of dopamine agonists, catechol-O-methyltransferase inhibitors, monoamine oxidase B inhibitors, anticholinergics, carbidopa-levodopa, and others. Dopamine agonists, for example, mimic dopamine's effects in the brain to help control symptoms. These drugs can be administered via various routes, including oral, injectable, intestinal infusion, subcutaneous, and other methods, depending on treatment requirements. Additionally, the distribution channels for Parkinson's disease medications include retail pharmacies, hospital pharmacies, and online pharmacies, ensuring broad accessibility. Most patient care for Parkinson's disease is managed in clinics and hospitals, where healthcare professionals can closely monitor and treat the condition.

The parkinson's disease market research report is one of a series of new reports from The Business Research Company that provides parkinson's disease market statistics, including parkinson's disease industry global market size, regional shares, competitors with a parkinson's disease market share, detailed parkinson's disease market segments, market trends and opportunities, and any further data you may need to thrive in the parkinson's disease industry. This parkinson's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The parkinson's disease market size has grown strongly in recent years. It will grow from $3.34 billion in 2024 to $3.63 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the increase in research and development, a rise in government funding, the expansion of personalized treatment plans, the growth of support networks for Parkinson's disease patients, and the increased use of advanced rehabilitation therapies.

The parkinson's disease market size is expected to see strong growth in the next few years. It will grow to $4.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth projected for the forecast period is driven by increased awareness of Parkinson's disease symptoms, enhanced government initiatives, rising healthcare spending, a growing number of clinical trials for Parkinson's disease, and greater adoption of gene therapies. Key trends during this period include technological advancements, continued government initiatives and funding, the integration of artificial intelligence in diagnosis, innovative solutions, and a move toward personalized medicine.

The increasing prevalence of neurodegenerative diseases is expected to drive the growth of the Parkinson's disease market. Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration and loss of function of neurons in the brain and nervous system. Several factors contribute to the rising prevalence of these conditions, including an aging population, genetic predisposition, environmental influences, improved diagnosis, chronic health conditions, and lifestyle changes. Parkinson's disease plays a crucial role in advancing the understanding of neurodegenerative diseases by offering insights into their underlying mechanisms, identifying potential therapeutic targets, and developing innovative treatment approaches. For instance, in April 2022, the European Brain Council reported that over 600 neurological diseases and nearly 300 psychiatric conditions affect millions globally, with 65 million people suffering from epilepsy. In Europe alone, 10.5 million people have dementia, with projections indicating an increase to 18.7 million by 2050. As a result, the rising prevalence of neurodegenerative diseases is fueling the expansion of the Parkinson's disease market.

Leading companies in the Parkinson's disease market are focusing on innovative treatment solutions, such as levodopa-based therapy, to enhance motor function and provide continuous symptom management for patients with advanced Parkinson's disease. Levodopa-based therapy involves using levodopa, a medication that converts into dopamine in the brain, to alleviate symptoms and improve motor function. For example, in October 2024, AbbVie Inc., a U.S.-based biopharmaceutical company, received FDA approval for VYALEV, a combination therapy containing levodopa and carbidopa designed for treating Parkinson's disease. This formulation enhances the efficacy of levodopa by preventing its breakdown before reaching the brain, thereby increasing dopamine levels. The medication effectively manages motor symptoms such as tremors, rigidity, and bradykinesia, helping patients maintain daily activities and improving their quality of life. It is considered a key therapeutic solution for patients with Parkinson's disease experiencing motor fluctuations.

In August 2024, AbbVie Inc. expanded its neuroscience portfolio by acquiring Cerevel Therapeutics Holdings Inc., a US-based biotechnology company specializing in treatments for Parkinson's disease. This acquisition aims to strengthen AbbVie's position in addressing unmet medical needs in psychiatric and neurological disorders, reinforcing its commitment to developing innovative therapies for neurodegenerative diseases.

Major players in the parkinson's disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

North America was the largest region in the parkinson's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in parkinson's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the parkinson's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The parkinson's disease market consists of revenues earned by entities providing services such as speech therapy, and physical therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The parkinson's disease market also includes sales of amantadine and adenosine A2A receptor antagonists. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Parkinson's Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on parkinson's disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for parkinson's disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The parkinson's disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Dopamine Agonists; Catechol-O-Methyltransferase Inhibitors; Monoamine Oxidase B Inhibitors; Anticholinergics; Carbidopa-Levodopa; Other Drug Classes
• 2) By Route Of Administration: Oral; Injectable; Intestinal infusion; Subcutaneous; Other Route Of Administrations
• 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies
• 4) By Patient Care Setting: Clinics; Hospitals
• Subsegments:
• 1) By Dopamine Agonists: Ergot Derivatives; Non-Ergot Derivatives
• 2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone; Tolcapone; Opicapone
• 3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline; Rasagiline; Safinamide
• 4) By Anticholinergics: Trihexyphenidyl; Benztropine; Procyclidine
• 5) By Carbidopa-Levodopa: Immediate-Release Formulation; Extended-Release Formulation; Inhaled And Intestinal Gel Formulations
• 6) By Other Drug Classes: Amantadine And Derivatives; Adenosine A2A Receptor Antagonists; Glutamate Antagonists
• Companies Mentioned:Roche Holding AG; AbbVie Inc.; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; UCB S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Parkinson's Disease Market Characteristics

3. Parkinson's Disease Market Trends And Strategies

4. Parkinson's Disease Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Parkinson's Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Parkinson's Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Parkinson's Disease Market Growth Rate Analysis
• 5.4. Global Parkinson's Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Parkinson's Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Parkinson's Disease Total Addressable Market (TAM)

6. Parkinson's Disease Market Segmentation

• 6.1. Global Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dopamine Agonists
• Catechol-O-Methyltransferase Inhibitors
• Monoamine Oxidase B Inhibitors
• Anticholinergics
• Carbidopa-Levodopa
• Other Drug Classes
• 6.2. Global Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Intestinal infusion
• Subcutaneous
• Other Route Of Administrations
• 6.3. Global Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• 6.4. Global Parkinson's Disease Market, Segmentation By Patient Care Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• 6.5. Global Parkinson's Disease Market, Sub-Segmentation Of Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ergot Derivatives
• Non-Ergot Derivatives
• 6.6. Global Parkinson's Disease Market, Sub-Segmentation Of Catechol-O-Methyltransferase (COMT) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Entacapone
• Tolcapone
• Opicapone
• 6.7. Global Parkinson's Disease Market, Sub-Segmentation Of Monoamine Oxidase B (MAO-B) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selegiline
• Rasagiline
• Safinamide
• 6.8. Global Parkinson's Disease Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trihexyphenidyl
• Benztropine
• Procyclidine
• 6.9. Global Parkinson's Disease Market, Sub-Segmentation Of Carbidopa-Levodopa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate-Release Formulation
• Extended-Release Formulation
• Inhaled And Intestinal Gel Formulations
• 6.10. Global Parkinson's Disease Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amantadine And Derivatives
• Adenosine A2A Receptor Antagonists
• Glutamate Antagonists

7. Parkinson's Disease Market Regional And Country Analysis

• 7.1. Global Parkinson's Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Parkinson's Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Parkinson's Disease Market

• 8.1. Asia-Pacific Parkinson's Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Parkinson's Disease Market

• 9.1. China Parkinson's Disease Market Overview
• 9.2. China Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Parkinson's Disease Market

• 10.1. India Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Parkinson's Disease Market

• 11.1. Japan Parkinson's Disease Market Overview
• 11.2. Japan Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Parkinson's Disease Market

• 12.1. Australia Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Parkinson's Disease Market

• 13.1. Indonesia Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Parkinson's Disease Market

• 14.1. South Korea Parkinson's Disease Market Overview
• 14.2. South Korea Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Parkinson's Disease Market

• 15.1. Western Europe Parkinson's Disease Market Overview
• 15.2. Western Europe Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Parkinson's Disease Market

• 16.1. UK Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Parkinson's Disease Market

• 17.1. Germany Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Parkinson's Disease Market

• 18.1. France Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Parkinson's Disease Market

• 19.1. Italy Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Parkinson's Disease Market

• 20.1. Spain Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Parkinson's Disease Market

• 21.1. Eastern Europe Parkinson's Disease Market Overview
• 21.2. Eastern Europe Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Parkinson's Disease Market

• 22.1. Russia Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Parkinson's Disease Market

• 23.1. North America Parkinson's Disease Market Overview
• 23.2. North America Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Parkinson's Disease Market

• 24.1. USA Parkinson's Disease Market Overview
• 24.2. USA Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Parkinson's Disease Market

• 25.1. Canada Parkinson's Disease Market Overview
• 25.2. Canada Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Parkinson's Disease Market

• 26.1. South America Parkinson's Disease Market Overview
• 26.2. South America Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Parkinson's Disease Market

• 27.1. Brazil Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Parkinson's Disease Market

• 28.1. Middle East Parkinson's Disease Market Overview
• 28.2. Middle East Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Parkinson's Disease Market

• 29.1. Africa Parkinson's Disease Market Overview
• 29.2. Africa Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Parkinson's Disease Market Competitive Landscape And Company Profiles

• 30.1. Parkinson's Disease Market Competitive Landscape
• 30.2. Parkinson's Disease Market Company Profiles
  • 30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. UCB S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Parkinson's Disease Market Other Major And Innovative Companies

• 31.1. Eisai Co. Ltd.
• 31.2. Kyowa Kirin Co. Ltd.
• 31.3. Amneal Pharmaceuticals Inc.
• 31.4. Neurocrine Biosciences Inc.
• 31.5. Supernus Pharmaceuticals Inc.
• 31.6. Sunovion Pharmaceuticals Inc.
• 31.7. Intracellular Therapies Inc.
• 31.8. Voyager Therapeutics Inc.
• 31.9. Sage Therapeutics Inc.
• 31.10. Adamas Pharmaceuticals Inc.
• 31.11. Sun Pharma Advanced Research Company Ltd.
• 31.12. Neuraly Inc.
• 31.13. Mitsubishi Tanabe Pharma Corporation
• 31.14. Athira Pharma Inc.
• 31.15. VistaGen Therapeutics Inc.

32. Global Parkinson's Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Parkinson's Disease Market

34. Recent Developments In The Parkinson's Disease Market

35. Parkinson's Disease Market High Potential Countries, Segments and Strategies

• 35.1 Parkinson's Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Parkinson's Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Parkinson's Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer